M
Marker Therapeutics, Inc. (MRKR)
NCM – Real Time Price. Currency in USD
1.44
-0.01 (-0.69%)
At close: May 12, 2026, 4:00 PM EDT
1.44
0.00 (0.00%)
After-hours: May 12, 2026, 7:39 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.44
-0.01 (-0.69%)
At close: May 12, 2026, 4:00 PM EDT
1.44
0.00 (0.00%)
After-hours: May 12, 2026, 7:39 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.39 | 6.05 | 10 | |
| Quick ratio | 8.39 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 4M | 3M | 7M | 4M | 4M |
| Gross Profit | 5M | N/A | N/A | N/A | N/A |
| Operating Income | -20M | -15M | -11M | -12M | -12M |
| Net Income | -30M | -17M | -11M | -12M | -12M |
| EBITDA | -20M | -15M | -11M | -12M | -12M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 95.39 | 54.31 | 10 |
| Next quarter | -22.54 | 12.72 | 4.5 |
| Current year | -24.01 | -25.87 | 1.0 |
| Next year | 644.03 | -2.19 | 5.5 |
| Weighted average score | 5.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -10.49 | 14.78 | 16.67 | 30.55 | 7.0 |
| Y/Y | -50.99 | 55.62 | 75.61 | 59.6 | 7.8 |
| 3y average | 15.71 | 22.24 | 26.92 | 20.86 | 9.8 |
| 5y average | 79.22 | 9.88 | 25.1 | 14.01 | 8.5 |
| Weighted average score | 8.3 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Cash reserves $17.0M barely cover the upcoming debt maturities $0.0
Total current assets $19.1M exceed Total current liabilities $2.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$1.9M limits the company's ability to reinvest or pay down debt